


ONC201 in H3 K27M-Mutant Diffuse Glioma

A European Association of Neuro-Oncology (EANO)
Annual Meeting (2022) Special Symposium

Saturday, 17 September
12:00-13:00

Künstlerzimmer Room
Mezzanine Level



ONC201, a first-in-class imipridone, has shown anti-cancer efficacy in patients with H3 K27M-mutant diffuse glioma.

JOIN US for a symposium discussing the development, recent findings, and future clinical evaluation of ONC201 in H3 K27M-mutant glioma in a Phase 3 trial.

Welcome & Introductory Remarks

• Allen Melemed, MD (Chimerix, Inc.)

12:00-12:05

ONC201: Mechanism of Action and Early Phase Development

• Joshua E. Allen, PhD (Chimerix, Inc.)

12:05-12:15

Clinical Efficacy and Safety in Diffuse Mutant Glioma

• Isabel Arrillaga-Romany, MD, PhD
(Massachusetts General Hospital)

12:15-12:30

ONC108, a Randomized Phase 3 Clinical Trial in Newly Diagnosed H3 K27M-mutant Diffuse Glioma

• Martin van den Bent, MD, PhD
(Brain Tumor Center at Erasmus MC Cancer Institute)

12:30-12:45

Panel Discussion and Q&A

• Panelists

12:45-13:00



Sponsored by Chimerix, Inc